The Dexcom Community Glucose Monitoring Project: Six-Month Results Using Continuous Glucose Monitoring in Type 2 Diabetes
Topics: Type 2 Diabetes, Primary Care, Lifestyle Modification
Research Spotlight: “The Dexcom Community Glucose Monitoring Project: Six-Month Results Using Continuous Glucose Monitoring in Type 2 Diabetes” Grace TP, et al. Clinical Diabetes. 2024;42(4):540-6.
Background: Glucose sensor use is limited in the primary care setting despite the multiple benefits of continuous glucose monitoring (CGM) among people with type 2 diabetes.
Key question: What are the benefits of a glucose sensor in type 2 diabetes in a real-world primary care setting?
Main outcomes of the study:
- Participants using a glucose sensor (n=237) showed clinically meaningful and statistically significant (p<0.001) decrease in A1C of 2.4%+1.9% at 6 months. Overall, those with higher baseline A1C achieved greater reductions in A1C at the 6-month follow-up.
- TIR 70-180 mg/dL significantly increased in the glucose sensor group by 5.5%±28.7% (p=0.022). The improvement in TIR was attributable to a significant decrease in TAR >180 mg/dL (p=0.021).
- The proportion of glucose sensor participants meeting Healthcare Effectiveness Data and Information Set (HEDIS) A1C Target of < 8.0% increased from 18.6% to 82.7% at 6 months.
Key takeaways for healthcare providers:
- Glucose sensor use in a real-world primary care type 2 diabetes population improved A1C and resulted in a greater proportion meeting A1C targets.
- Expanded use of glucose sensors in the primary care setting could help more patients learn about their diabetes, make and sustain lifestyle modifications, and achieve glycemic targets.
Related Content
Topics: Pregnancy, Accuracy, Safety Research Spotlight: “Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes” Polsky S, et al. Diabetes Technol Ther. 2024;26(5):307-12. Background...
Title: Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes Topics: Long-Term Outcomes, Type 2 Diabetes, Noninsulin-Treated Research...